Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29978443 | 1.00 | MEN1 (0.41) | MEN1KMT2ANAPRTALDH1A1KCNQ3 | |
| SCHEMBL29909266 | 0.82 | POLB (0.40) | NAPRTALDH1A1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL77078 | 0.82 | POLB (0.40) | NAPRTALDH1A1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL31000262 | 0.80 | GCK (0.46) | KCNQ3KCNQ2KCNE1KCNQ1GRM4 | |
| SCHEMBL5178358 | 0.80 | ALDH1A1 (0.37) | MEN1KMT2ANAPRTALDH1A1KCNQ3 | |
| SCHEMBL31000265 | 0.80 | GCK (0.46) | KCNQ3KCNQ2KCNE1KCNQ1GRM4 | |
| SCHEMBL18053748 | 0.80 | GCK (0.46) | KCNQ3KCNQ2KCNE1KCNQ1GRM4 | |
| SCHEMBL29879160 | 0.78 | KCNQ3 (0.42) | NAPRTALDH1A1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL9966941 | 0.78 | KCNQ3 (0.42) | NAPRTALDH1A1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL27311270 | 0.78 | ALDH1A1 (0.37) | NAPRTALDH1A1KCNQ3KCNQ2KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448492-B1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12404242-B2 | Compositions and methods for making and using small molecules in the treatment of cancer | REGLAGENE, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250109105-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE, INC. | 2025-04-03 | — | — | US | disclosed |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
| EP-4448492-A1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | Reglagene, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-3681883-B1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN | 2010-09-02 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-4474602-A | Substituted pyridyl compounds, herbicidal compositions and method of use | THE DOW CHEMICAL COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| US-4348396-A | Substituted 11-oxo-11H-pyrido[2,1-b]quinazolines and method of inhibiting allergic reactions with them | HOFFMANN-LA ROCHE INC. (US) | 1982-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | MEN1 142/4885KMT2A 394/4885NAPRT 223/4885 |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | MEN1 2673/4885KMT2A 1683/4885NAPRT 1832/4885 |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | MEN1 2818/4885KMT2A 1853/4885NAPRT 1753/4885 |
| US-20250109105-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | CD47, RB1, TP53 | MEN1 160/4885KMT2A 700/4885NAPRT 3036/4885 |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | MEN1 2818/4885KMT2A 1853/4885NAPRT 1753/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | MEN1 2646/4885KMT2A 1758/4885NAPRT 1658/4885 |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | MEN1 4537/4885KMT2A 2923/4885NAPRT 1961/4885 |
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | MEN1 3315/4885KMT2A 4164/4885NAPRT 2275/4885 |
| US-12404242-B2 | Compositions and methods for making and using small molecules in the treatment of cancer | CD47, RB1, TP53 | MEN1 160/4885KMT2A 700/4885NAPRT 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.